乳腺癌组织中C-erbB-2蛋白和MHCⅠ类分子表达与预后的关系

Relationship of the Expression of C-erbB-2 Protein and MHCⅠ Molecules with the Prognosis in Breast Cancer

目的了解乳腺癌组织中C-erbB-2蛋白和MHCⅠ类分子表达与预后的关系。方法58例乳腺癌根据有无淋巴结转移分为淋巴结转移组和淋巴结未转移组;根据组织学分级分为Ⅰ级、Ⅱ级和Ⅲ级。应用免疫组织化学S-P法检测乳腺癌组织C-erbB-2蛋白表达;应用流式细胞仪检测MHCⅠ类分子表达。结果乳腺癌淋巴结转移组C-erbB-2蛋白的阳性表达率(84.2%)明显高于淋巴结未转移组(41.0%);C-erbB-2蛋白在Ⅰ级、Ⅱ级和Ⅲ级的阳性表达率分别为42.1%、55.5%和75.0%;MHCⅠ类分子在Ⅰ级、Ⅱ级和Ⅲ级的阳性表达率分别为50.21%±15.70%、30.17%±16.23%和14.27%±9.36%。结论C-erbB-2蛋白和MHCⅠ类分子的表达可作为判断乳腺癌预后的重要指标。

Objective To study the relationship of the expression of C-erbB-2 protein and MHC Ⅰ molecules with prognosis in breast cancer. Methods Lymph nodes metastases were detected in 58 cases of breast cancer. The patients were also graded as stage Ⅰ ,stage Ⅱ and stage Ⅲ diseases according to the histological examination. The expression of C-erbB-2 and MHC Ⅰ molecules was detected by immunohistochemistry method and flow cytometry,respectively. Results The positive expression rate of C-erbB-2 protein was higher in patients with lymph node metastases than in patients without（84.2% v.s. 41.0% ）. The positive expression rate of C-erbB-2 protein in stage Ⅰ ,stag Ⅱ and stage Ⅲ diseases was 42.1% ,55.5% and 75.0% respectively. The positive expression rate of MHC Ⅰ molecules in stage Ⅰ ,stag Ⅱ and stage Ⅲ diseases was 50.21%, 30.17%, 14.27%,respectively. Conclusion The expression of C-erbB-2 protein and MHC Ⅰ molecules can be regard as important prognosis factors in breast cancer.